Genotype |
Allele |
Population |
Type and size of the study |
Association |
OR / RR |
References |
ERα351 Xbal A/G |
AA |
Norway 27 to 94 years-old |
Case / control 360/672 |
↑ risk for breast cancer after menopause |
OR: 2.02
IC 95%: 0.96-4.31 |
Andersen et al. [18] |
|
AA |
Korea |
Case / control 205/205 |
↑ risk for breastcancer |
OR: 2.38
IC 95%: 1.58-3.58 |
Shin et al. [6] |
|
AA |
Korea |
Case / control 205/205 |
↑ risk for breast cancer in nulliparous |
RR: 4.0
IC 95%: 1.9-8.8 |
Shin et al. [6] |
|
AA |
Netherlands and England
After- menpausa |
Cohort prospective 791withHT / 781 no HT |
↑mammographic density in HT users |
2,20%
p<0,01 |
vanDuijnhoven et al. [17] |
|
AA |
China |
|
↑ risk for breastcancer |
OR: 6.88
IC 95%: 0.80-59.15 p=0.079 |
Hu et al. [19] |
|
AA |
China
25-55 years-old |
Case / control |
↑ risk for breast cancer, with positive family history |
OR: 4.20
IC 95%: 0.65-27.28 |
Shen et al. [12] |
|
AA |
Netherlands
55 yearsor more |
Case / control 190/3513 |
↑ risk for breast cancer in women after menopause |
OR: 1.3
IC 95%: 0.7-2.2 |
Ladd et al. [14] |
|
AA |
Brazil
After -menopause |
Prospective
120 |
↑ higherbreastdensity |
OR: 2.34
IC95%:1.06-5.16 p=0.03 |
Ramos et al. [20] |
|
|
England |
Systematic review of case-control studies |
Nonsignificantdifference |
P=0,06 |
Dunning et al. [21] |
|
AA |
Pakistan, 15-65 years-old |
Case / control 100/100 |
↑ of the risk of BC post menopouse |
AA 45%
greater than GG
p<0.01 |
Javed et al. [22] |
|
AA |
BrazilAfter -menoppausa |
Only cases
308 women |
Mammographicdensity> 50% |
AA 33,44%
greaterthan GG 16,56% |
Souza et al. [16] |
HaplotypXbal -C975→G |
|
SwedenAfter- menoppausa |
Case / control 1556/1512 |
↑ risk of breast cancer in postmenopausal and obese women |
OR=1,48
IC 95%: 1,17-1,88 |
Wedren et al. [23] |
|
AG |
Norway 27-94 years-old |
Case / control 360/672 |
↑ risk for breastcancer |
OR: 2.00
IC 95%: 0.92-4.37 |
Andersen et al. [18] |
|
GG |
USA, Caucasian greater than 65 years-old |
Case / control 393/790 |
↓ risk for breastcancer |
OR 0.82
IC 95%: 0.68-1.00
P= 0.04 |
Wang et al. [24] |
|
GG |
Netherlands and England After- menopause |
Prospective Cohort 795 with HT / 781 no HT |
Mammographic density without changes in users of HT |
0,65%
p= 0.70 |
van Duijnhoven et al.[17] |
|
A |
China |
Case / control 114/121 |
↑ risk for breastcancer |
OR: 1.4
IC 95%: 1.0-1.9 |
Hu et al. [19] |
|
G |
Korea |
Case / control 205/205 |
↓ risk for breast cancer in postmenopausal |
RR: 0.3
IC 95%: 0.1-0.5 |
Shin et al. [6] |